Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Lymphoma
Would you substitute vinblastine for vincristine in RCHOP?
There is a national shortage of vincristine.
Answer from: Medical Oncologist at Academic Institution
It’s not a good idea since vinblastine is myelosuppressive, unlike vincristine, and not well studied in NHL.
Comments
Medical Oncologist at Allina Health Cancer Institute
Thank you for your input, @James O. Armitage. ...
2244
Sign In
or
Register
to read more
6584
Related Questions
How would you manage a patient with a recent diagnosis of advanced DLBCL (non-GCB subtype) who has baseline grade 3 neuropathy?
How would you approach treatment with BV-CHP regimen in a patient with newly diagnosed CD30+ ALK- anaplastic large cell lymphoma at high risk for cardiotoxicity?
How would you structure your monitoring for a low-risk leukemic TP53-negative mantle cell lymphoma with 5% MCL cells detected in both peripheral blood and bone marrow, mild splenomegaly, and no lymphadenopathy or B symptoms?
In light of data from TRIANGLE, ECHO, and ENRICH, what is the best strategy to treat newly diagnosed patients with the blastoid variant MCL?
Do you utilize ctDNA-based MRD testing after frontline chemotherapy for DLBCL?
What is your approach to treatment of mantle cell lymphoma in someone with a mutated gene downstream of the BTK receptor, such as mutated CARD11. Have you seen frontline resistance to BTKi in this case and would you thus go with a chemo based regimen?
How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?
Has the data for the ENRICH study changed your practice for the initial treatment of mantle-cell lymphoma?
What is the role of surveillance imaging after first line therapy in patients with aggressive lymphomas?
How would you manage a stage IE Burkitt lymphoma with stable disease after three cycle of DA-R-EPOCH?
Thank you for your input, @James O. Armitage. ...